BRUSSELS (Reuters) – Israeli drugmaker Teva rebuffed EU antitrust charges of making an illegal deal with rival Cephalon to delay selling a cheaper generic version of the latter’s sleep disorder drug at a hearing on Tuesday.
Source: Reuters Medical News